Badrilla
|
|
|
|
New phospho-specific antibodies released 9th December 2006: Badrilla announces the release of two new phospho-specific antibodies to SERCA2 phosphorylated on Ser-38 and CaMkinase II phosphorylated on Thr-286 or -287 (depending on the isoform in question). These antibodies are both rabbit polyclonal antibodies, and have the same high standard of specificity which is enjoyed throughout our product range. Antibodies are provided in pack sizes capable of performing numerous Western blots (100mL), approximately 20 mini-gel blots in our experience. The antibody to phospho-SERCA is accompanied by a positive control sample, as we have not to date identified conditions which provoke phosphorylation of this protein in biological specimens.
Calibration Tools for Quantitative Biology: a vital step forward 26th July 2005: Badrilla announces the publication of a simple calibration technology capable of providing wholly quantitative data from immunoassays, including western blots. This will permit description of the number of moles of each component of interest in a biological specimen, bringing new clarity to molecular descriptions of biological and biomedical processes. Modern biological research seeks to describe the molecular events underlying important natural phenomena, which requires quantitative information regarding all parameters in a system. This includes definition of the concentration of components (proteins) in a system and their activity, which is often regulated by their state of phosphorylation. At present these simple parameters are unknown, as the data generated relate to the intensity of the immunosignal observed, rather than the concentration of component of interest. The relationship between these two parameters (signal intensity and antigen concentration) is unknown, which prevents the quantitative description of the system under study. To overcome this limitation, Badrilla has created a calibration technology, which will be delivered to scientists as a simple accessory reagent, to calibrate the signals generated from their most popular techniques (Western blot, ELISA). This will permit calculation of the concentration of each component (protein, phosphoprotein) in a specimen, and will take biological research to a new, wholly quantitative level. The technology presents a defined concentration of epitope features (the feature recognised by an antibody) fused to a presentation molecule of known molecular weight and pI, which ensures that the product is homogeneous in character, and possesses physical characteristics suited to the experimental procedure of the researcher (Rodriguez et al. (2004) J. Biol. Chem. 279, 17111; Colyer (2005) patent PCT/GB05/000015). A serial dilution of this product defines the relationship between antibody signal intensity and the concentration of the molecule of interest, thereby calibrating all experimental data. Enquiries and requests for further information should be directed to John Colyer at
New anti-phospho-PLB (Thr-17) antibody 7th June 2003: Badrilla launches new antibody to Thr-17 phosphorylated PLB with the same quality as the previous serum, but with greater apparent sensitivity. As the stocks of the original anti-phospho-PLB (Thr-17) reduced, we have explored the properties of sera obtained from the immunisation of other rabbits. One such serum displayed outstanding results, with greater stability than the original serum and greater sensitivity, whilst retaining the quality of discrimination between phosphorylation sites which all researchers require. This serum (LOT 0503-01) has now replaced the original antiserum and is distributed under catalogue A010-13. It should be noted that a non-specific interaction between antibodies in this serum (0503-01) and a protein of ~30kDa is observed in rat cardiac homogenates. The interaction is not affected by epitope peptide and thus is unrelated to PLB. We recommend, as always, that specific interactions are identified through the use of epitope peptides in all experiments performed. An example of such an experiment is shown in our data sheet (LOT 0503-01). Epitope peptides are available to all antibodies distributed by Badrilla.
Badrilla licenses antibodies and technology from PPR 09 Feb 2002: Badrilla is pleased to announce the licensing of phosphorylation-status specific antibodies from PhosphoProtein Research (PPR). PPR has pioneered the development of phosphorylation-status specific antibodies, and has set the standard for this field in cardiac muscle . A suite of antibodies previously available through PPR plus new ranges not previously released will be distributed and supported by Badrilla from today. Badrilla is a life science reagents company based in Yorkshire, England. It has been founded by scientists active in signal transduction research, to distribute reagents for the study of post-translational modification events, which are of the highest quality. The company aims to provide the best quality service and reagents for researchers in the field of post-translational modification research, and seeks to develop novel technologies for this field which both accelerate the rate of progress and increase the information content of research conducted.
Opening offer from Badrilla 09 Feb 2002: To mark the distribution of phosphorylation-status specific antibodies by Badrilla, promotional discounts of 20% are offered on all orders received in February & March 2002. Antibodies to key proteins in cardiac E-C coupling are currently available including phosphorylation-specific antibodies to phospholamban and the ryanodine receptor. Badrilla antibodies deliver exhilarating performance!
Badrilla web site: This site is new. It has been created to provide you with round-the-clock access to the products available at Badrilla, including the technical specification of batches in current use, and the step-by-step protocols we recommend for the use of these reagents. We seek to make premium quality materials available to the phosphorylation research field. If you have developed such materials and would like to discuss the marketing of these probes with us, we would be delighted to speak with you. Please see the In-Licensing section of this site and contact us at licence@badrilla.com We welcome any feedback you have about the site, particularly comments on improvements to the content and ease of use.
|
|
Send mail to web@badrilla.com with
questions or comments about this web site.
|
